New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Canadian Agency for Drugs and Technologies in Health. New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Therapeutic Review. 2012

Authors' objectives
Compare the clinical effectiveness and safety of these anticoagulants with warfarin Determine the cost and economic impact of these anticoagulants compared with warfarin Compare these anticoagulants with optimal warfarin therapy Review available strategies to identify over-anticoagulation and bleeding risk with new oral anticoagulants Review available strategies to prevent and treat bleeding associated with new oral anticoagulants Develop recommendations for the use of new oral anticoagulants Determine what tools are available to help health practitioners and consumers manage therapy with new oral anticoagulants and, if needed, develop new tools

Authors' conclusions
Compared with warfarin, the benefits of new oral anticoagulants are small. The estimated number of patients who would avoid a stroke or other blood clot if treated with a new drug rather than warfarin was 2 to 6 people for every 1,000 patients treated per year. Bleeding risks for patients treated with the newer drugs compared with warfarin were similar overall, with a modest decrease in intracranial bleeding and a small increase in gastrointestinal bleeding. A systematic review showed that there is no reversal agent or proven management strategy if bleeding occurs with the new drugs. The cost-effectiveness of the new drugs was uncertain.

Final publication URL
http://www.cadth.ca/en/products/therapeutic-reviews/anticoagulants/reports

Indexing Status
Subject indexing assigned by CRD

MeSH
Anticoagulants; Thromboembolism; Venous Thrombosis

Language Published
English

Country of organisation
Canada

Province or state
Ontario

English summary
An English language summary is available.

Address for correspondence
865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: htainfo@cadth.ca
AccessionNumber
32010001163

Date abstract record published
20/10/2010